Offical Claris Bio Logo - no background  - Logo over words.png
Claris Bio Emerges From Stealth With a New Investor and Prepares for Next Development Stage With Late-Stage Data Expected in 1H24
January 04, 2024 08:00 ET | Claris Biotherapeutics, Inc.
Claris Bio emerges from stealth with $57 million in funding as it prepares for 1H2024 readout of late-stage study in neurotrophic keratopathy
2020-0227 Cognition Logo for GNW.png
Cognition Therapeutics Announces Participation in Upcoming September Conferences
August 30, 2023 08:00 ET | Cognition Therapeutics, Inc.
PURCHASE, N.Y., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by...
Frontera Therapeutics Doses First Patient in a Clinical Trial of FT-003 Gene Therapy for the Treatment of Wet AMD
February 02, 2023 09:00 ET | Frontera Therapeutics
BEDFORD, Mass. and SHANGHAI, China, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Frontera Therapeutics, a global clinical-stage biotechnology company that seeks to develop novel and best-in-class gene therapy...
Investigational Optejet® Microdose Dispenser from Eyenovia Shows Promise in Improving Treatment for Myopia, Presbyopia and Patients Getting Eye Exams
October 17, 2022 09:01 ET | Eyenovia
NEW YORK, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Two recent studies show that the novel Optejet® dispenser from Eyenovia, Inc., an ophthalmic pharmaceutical technology company, may be a more...
Dr. Sean Ianchulev
Eyenovia Chairman Dr. Sean Ianchulev: The Making Of An iDoctor - Immigrant, Innovator, Inventor
September 21, 2022 10:01 ET | Eyenovia
NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Before founding Eyenovia, Dr. Sean Ianchulev had established himself as a pioneer and innovator in the field of ophthalmology. Inspired by his mother, a...
Eyenovia Optejet Gen2 Device
Eyenovia's Novel Optejet® Dispenser Puts People's Eyes First
August 30, 2022 09:01 ET | Eyenovia
NEW YORK, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, brings...
Saturn-1 patients' collarettes at baseline and post treatment
Tarsus Pharmaceuticals, Inc. Announces Positive Results of Saturn-1 Pivotal Trial Evaluating TP-03 for the Treatment of Demodex Blepharitis
June 21, 2021 06:00 ET | Tarsus Pharmaceuticals, Inc
Saturn-1 Phase 2b/3 trial met all primary and secondary endpoints, and demonstrated significant, clinically meaningful outcomes with no serious treatment-related adverse events and no...
Notal Vision secures
Notal Vision secures $25 million in recent funding round for ForeseeHome® and pipeline technologies
December 11, 2019 08:00 ET | Notal Vision
Manassas, VA, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Notal Vision, Inc., a privately held ophthalmic diagnostic services company focused on advancing eye care with precision medicine by extending disease...
EyeGate Announces Po
EyeGate Announces Positive Top-line Data from Phase 1b/2a Clinical Trial of EGP-437 for Treatment of Post-Operative Inflammation and Pain in Cataract Surgery Patients
August 01, 2016 08:30 ET | EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Aug. 01, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...
CooperCompanies Aqua Logo-HORZ.jpg
The Cooper Companies Reports First Quarter 2004 Results and Updates Guidance
March 02, 2004 16:00 ET | The Cooper Companies, Inc.
Fiscal 2004 Guidance Raised: Revenue $480 Million to $490 Million; EPS $2.51 to $2.54 Second Quarter 2004 Guidance: Revenue $114 Million to ...